Lv21
200 积分 2026-03-02 加入
The evolving landscape of drug targets
6天前
已完结
Treatment Decisions in Multiple Myeloma
6天前
已完结
Esophageal Cancer
6天前
已完结
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages
9天前
已完结
ENIGMA CHEK2 gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
9天前
已完结
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages
9天前
已完结
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
14天前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
14天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
14天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
14天前
已完结
皖公网安备34019202002308
